Tohru Mizushima - Pharma

Author Information

Tohru Mizushima is a prominent researcher affiliated with the Department of Drug Discovery and Development at the Faculty of Pharmacy, Keio University, located in Tokyo, Japan. His research is primarily focused on pharmacology and drug development, contributing significantly to the field through various innovative studies and publications.

Research Contributions

Tohru Mizushima has made substantial contributions to the field of pharmacology, particularly in the study and development of therapeutic agents for conditions such as pulmonary fibrosis, ischemia/reperfusion injury, and inflammatory pain. His research explores novel pharmacological effects, including the use of eperisone to treat pulmonary fibrosis and the development of compounds with bronchodilatory and anti-inflammatory properties. His work on idebenone and mepenzolate derivatives further highlights his focus on optimizing drug efficacy and safety.

Aliases

Throughout his career, Tohru Mizushima has been recognized by several aliases, including T Mizushima and T. Mizushima, though his full name, Tohru Mizushima, is the most comprehensive and appropriate for formal recognition.

Publication and Citation Metrics

Metric	Value
Total Citation Count	10,348
h-index	54
Total Number of Papers	311

Publications:

Eperisone treats pulmonary fibrosis via preferential cell death induction in lung fibroblasts

DOI: 10.1254/jpssuppl.95.0_1-p-055

Year: 2022

Therapeutic effects of eperisone on pulmonary fibrosis via preferential suppression of fibroblast activity

DOI: 10.1038/s41420-022-00851-7

Year: 2022

Novel pharmacological effects of lecithinized superoxide dismutase on ischemia/reperfusion injury in the kidneys of mice.

DOI: 10.1016/j.lfs.2021.120164

Year: 2021

A2B adenosine receptor inhibition by the dihydropyridine calcium channel blocker nifedipine involves colonic fluid secretion

DOI: 10.1038/s41598-020-60147-7

Year: 2020

Nano PGE1 Enhances Phosphorylation of ERK1/2 and Akt to Promote Recovery from Motor Dysfunction and Muscle Atrophy Induced by Sciatic Nerve Injury

DOI: 10.20944/preprints201901.0250.v1

Year: 2019

Idebenone has preventative and therapeutic effects on pulmonary fibrosis via preferential suppression of fibroblast activity

DOI: 10.1038/s41420-019-0226-y

Year: 2019

Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity.

DOI: 10.1016/j.bmc.2019.06.016

Year: 2019

Antinociception by fluoro‐loxoprofen, a novel non‐steroidal anti‐inflammatory drug with less ulcerogenic effects, in rat models of inflammatory pain

DOI: 10.1016/j.ejphar.2018.12.008

Year: 2019

Identification of Mepenzolate Derivatives With Long-Acting Bronchodilatory Activity

DOI: 10.3389/fphar.2018.00344

Year: 2018

Ameliorative effect of chlorpromazine hydrochloride on visceral hypersensitivity in rats: possible involvement of 5‐HT2A receptor

DOI: 10.1111/bph.13960

Year: 2017

Why are Collaborative Care Models Important in Pharma?

What is an Abbreviated New Drug Application (ANDA)?

What is the Future of the Pharmacy Profession?

What Are Clinical Trials?

What are the Implications for Pharma Companies?

What Role Does Technology Play?

What Challenges Do Pharmacists Face?

How Can Pharmacists Contribute to Transitional Care?

Why is Transitional Care Important in Pharma?

How are ADEs Different from Side Effects?

Partnered Content Networks

Relevant Topics